Actively Recruiting
Prevent Cardiac Surgery Associated AKI Trial
Led by George Washington University · Updated on 2025-10-08
242
Participants Needed
1
Research Sites
204 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Prevent CSA-AKI (Cardiac Surgery Associated Acute Kidney Injury) trial is a double blinded randomized controlled trial, 242 patients undergoing elective cardiopulmonary bypass surgery (CPB)will either receive a placebo or daily 1200 mg of Co enzyme Q10 (CoQ10) and 1000 mg of Glutathione (GSH), the first dose will be given the day before surgery and continues while admitted up to 1 week. Blood and urine samples will be collected. Adverse events related to the study drugs will be collected.
CONDITIONS
Official Title
Prevent Cardiac Surgery Associated AKI Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 to 70 years
- Undergoing elective cardiopulmonary bypass (CPB) surgery
- Baseline glomerular filtration rate (GFR) of 45 ml/min or higher
You will not qualify if you...
- Glomerular filtration rate (GFR) below 45 ml/min
- Having a solitary kidney
- History of kidney transplant
- Pregnant women
- Allergy to Coenzyme Q10
- Allergy to Glutathione
- Allergy to cellulose
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
George Washington University Hospital
Washington D.C., District of Columbia, United States, 20037
Actively Recruiting
Research Team
E
Eduard Shaykhinurov, MS
CONTACT
Y
Yoosif Abdalla, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here